Cargando…

The Therapeutic Synergy of Selinexor and Venetoclax in Mantle Cell Lymphoma Through Induction of DNA Damage and Perturbation of the DNA Damage Response

Introduction: Mantle cell lymphoma (MCL) can be stratified into blastoid and classical subtypes based on morphological features, with the former subtype having a poorer prognosis. Despite recent advances in targeted approaches, including multiple bruton tyrosine kinase inhibitors which yield impress...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Sheng, Zuo, Wei, Liu, Tingting, Fu, Huan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605683/ https://www.ncbi.nlm.nih.gov/pubmed/37880950 http://dx.doi.org/10.1177/15330338231208608

Ejemplares similares

Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents
por: Kashyap, Trinayan, et al.
Publicado: (2018)

Selinexor Synergistically Promotes the Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia by Inhibiting Glycolytic Function and Downregulating the Expression of DNA Replication Genes
por: Jiang, Jiqian, et al.
Publicado: (2023)

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
por: Portell, Craig A., et al.
Publicado: (2022)

P1259: CHARACTERIZATION OF VENETOCLAX RESISTANCE IN CELL MODELS OF MANTLE CELL LYMPHOMA
por: Granau, A., et al.
Publicado: (2022)

A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma
por: Sawalha, Yazeed, et al.
Publicado: (2023)

Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
por: Nguyen, Nina, et al.
Publicado: (2022)

Profiling DNA damage response following mitotic perturbations
por: S. Pedersen, Ronni, et al.
Publicado: (2016)

Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma
por: Lakhotia, Rahul, et al.
Publicado: (2022)

Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor
por: Sgherza, Nicola, et al.
Publicado: (2021)

Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma
por: Phillips, Tycel J., et al.
Publicado: (2023)

Inhibition of cyclin‐dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma
por: Zhao, Xiaoxian, et al.
Publicado: (2020)

Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma
por: Thus, Yvonne J., et al.
Publicado: (2022)

PB1872: SELINEXOR IN COMBINATION WITH VENETOCLAX AND HYPOMETHYLATING AGENTS FOR ACUTE MYELOID LEUKEMIA PATIENTS WITH SEVERE CO-MORBIDITIES
por: Chen, Fangli, et al.
Publicado: (2023)

Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma
por: Liu, Yang, et al.
Publicado: (2022)

Nickel Carcinogenesis Mechanism: DNA Damage
por: Guo, Hongrui, et al.
Publicado: (2019)

P1246: DIFFERENTIAL ROLE OF MICROENVIRONMENT AND STROMAL-CELL INDUCED VENETOCLAX RESISTANCE IN MANTLE CELL LYMPHOMA
por: Andersen, P., et al.
Publicado: (2022)

Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation
por: Thus, Yvonne J., et al.
Publicado: (2022)

The potential role of COVID-19 in the induction of DNA damage
por: Pánico, Pablo, et al.
Publicado: (2022)

P426: HDAC INHIBITORS RESTORE SENSITIVITY TO VENETOCLAX AND NAVITOCLAX IN AML CELLS RESULTING IN THE IRREVERSIBLE DNA DAMAGE
por: Khabusheva, Elmira, et al.
Publicado: (2023)

Upregulation of Mcl-1S Causes Cell-Cycle Perturbations and DNA Damage Accumulation
por: Streletskaia, Alena Y., et al.
Publicado: (2020)

Concurrent Inhibition of Akt and ERK Using TIC-10 Can Overcome Venetoclax Resistance in Mantle Cell Lymphoma
por: Granau, Agnete Marie, et al.
Publicado: (2023)

Therapeutic Targeting of DNA Damage Response in Cancer
por: Choi, Wonyoung, et al.
Publicado: (2022)

DNA Damage and Its Role in Cancer Therapeutics
por: Moon, Jaeyoung, et al.
Publicado: (2023)

Type I Interferon Induction in Cutaneous DNA Damage Syndromes
por: Klein, Benjamin, et al.
Publicado: (2021)

Engineering a DNA damage response without DNA damage
por: Yeung, ManTek, et al.
Publicado: (2008)

DNA Damage and DNA Damage Response in Chronic Myeloid Leukemia
por: Popp, Henning D., et al.
Publicado: (2020)

Perturbation of DNA repair pathways by proteasome inhibitors corresponds to enhanced chemosensitivity of cells to DNA damage-inducing agents
por: Takeshita, Takashi, et al.
Publicado: (2009)

Deregulation upon DNA damage revealed by joint analysis of context-specific perturbation data
por: Szczurek, Ewa, et al.
Publicado: (2011)

Programmed DNA Damage and Physiological DSBs: Mapping, Biological Significance and Perturbations in Disease States
por: Oster, Sara, et al.
Publicado: (2020)

Perturbations of the endocannabinoid system in mantle cell lymphoma: correlations to clinical and pathological features
por: Wasik, Agata M., et al.
Publicado: (2014)

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
por: Wang, Michael, et al.
Publicado: (2021)

Polatuzumab‐bendamustine‐rituximab as bridge to CD19‐directed CAR T cells in mantle cell lymphoma refractory to ibrutinib and venetoclax
por: Perriello, Vincenzo Maria, et al.
Publicado: (2023)

The Intersection of DNA Damage Response and Ferroptosis—A Rationale for Combination Therapeutics
por: Chen, Po-Han, et al.
Publicado: (2020)

Interplay of space radiation and microgravity in DNA damage and DNA damage response
por: Moreno-Villanueva, María, et al.
Publicado: (2017)

Synergy between SIRT1 and SIRT6 helps recognize DNA breaks and potentiates the DNA damage response and repair in humans and mice
por: Meng, Fanbiao, et al.
Publicado: (2020)

CtIP is required for DNA damage-dependent induction of P21
por: Liu, Bo, et al.
Publicado: (2014)

Induction of oxidative stress, apoptosis and DNA damage by koumine in Tetrahymena thermophila
por: Ye, Qiao, et al.
Publicado: (2019)

Strategies for targeting the DNA damage response for cancer therapeutics
por: Zhang, Dan, et al.
Publicado: (2012)

Endothelial perturbations and therapeutic strategies in normal tissue radiation damage
por: Korpela, Elina, et al.
Publicado: (2014)

Mitochondrial protein-linked DNA breaks perturb mitochondrial gene transcription and trigger free radical–induced DNA damage
por: Chiang, Shih-Chieh, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_43cap0vqbr460so7mu6310se6t